Sustainable Insight Capital Management (SICM) focuses on institutional investments, offering both long-only and long-short strategies in public equities.
The semaglutide shortage has officially ended in the US—which means the GLP-1 drug industry is about to undergo massive ...
Resmed has its origins in the 1980s, when Sydney sleep expert Dr Colin Sullivan converted a vacuum cleaner to deal with the ...
Beyond treating diabetes and helping people lose weight, GLP-1s may also improve libido. But the reasons are as complex as ...
Lilly's Zepbound, which belongs to the widely popular ... adding that he expects these developments to drive more patients to use their devices. There are about 30 million adults in the U.S ...
ResMed’s strong demand for AirSense 11 boosts its earnings outlook. Learn why RMD stock is undervalued with growth ...
Inspire Medical shares dipped — but have since mostly recovered — following news of a government investigation following Q4 ...
And Allurion Technologies (ALUR) has developed a swallowable balloon device for weight loss that ... marketed and sold as Mounjaro (diabetes) and Zepbound (obesity), and Novo Nordisk’s (NVO ...
Released on Friday, February 7, the January jobs report showed resilience in the labor market with higher-than-expected wage ...
According to Bank of America, several companies are prime candidates for a stock split in the near future, which could lead to shares doubling the average market return, if historical trends are any ...
Here are 5 of CFRA analysts' top growth stocks that have reported at least 15% annual revenue growth in the past three years.
Some analysts expect demand for ResMed's CPAP devices to be disrupted by the U.S. approval for Eli Lilly's weight-loss drug Zepbound to treat the condition in overweight or obese adults.